RESPIRATORY SYNCYTIAL VIRUS (RSV)

This study looks at how well the RSV vaccine (ABRYSVO) given to pregnant women protects their babies from severe RSV disease that requires hospital care. Researchers will review health records of infants up to 12 months old who were hospitalized with respiratory illness in Austra…

This early-stage study tests an experimental mRNA vaccine called JCXH-108 designed to prevent respiratory syncytial virus (RSV) infection. About 75 healthy adults, split into two age groups (18-45 and 60+), will receive either the vaccine or a placebo. Researchers will closely mo…

This study checks how well the ABRYSVO vaccine works when given to pregnant people to protect their babies from RSV, a serious lung infection. Researchers will compare nearly 40,000 babies born to vaccinated and unvaccinated mothers, tracking infections and hospital visits up to …

This study looks at how the RSV vaccine affects the immune system in adults aged 60 and older. Researchers will take blood samples to measure antibodies and other immune markers after vaccination. The goal is to learn more about how the vaccine works and find early signs of a str…

This study looks at whether the respiratory syncytial virus (RSV) can pass from a pregnant woman to her unborn baby. Researchers will test blood from mothers and umbilical cords to check for RSV and other viruses. They will also follow the children for up to 4 years to see if the…